Avecho Biotechnology Limited (ASX:AVE)

Market Cap	45.97M +262.1%
Revenue (ttm)	1.24M +9.3%
Net Income	-4.42M
EPS	-0.00
Shares Out	3.83B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,754,033
Open	0.0120
Previous Close	0.0120
Day's Range	0.0110 - 0.0120
52-Week Range	0.0030 - 0.0140
Beta	1.18
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 4, 2026

About Avecho Biotechnology

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 15
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AVE

Financial Performance

In 2025, Avecho Biotechnology's revenue was 1.24 million, an increase of 9.28% compared to the previous year's 1.13 million. Losses were -4.42 million, 41.5% more than in 2024.